Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor
- PMID: 8200975
- PMCID: PMC294448
- DOI: 10.1172/JCI117248
Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor
Abstract
Platelet-activating factor (PAF) can exert profound inflammatory effects at very low concentrations. In plasma, PAF is hydrolyzed to lyso-PAF by acetylhydrolase, an enzyme that circulates bound to LDL. Previous studies suggest that oxygen radicals may act synergistically with PAF to potentiate tissue injury. However, mechanisms underlying this interaction have not been elucidated. In this study we investigated whether oxygen radicals may inactivate PAF acetylhydrolase. PAF acetylhydrolase activity was measured in human plasma and purified LDL before and after exposure to radicals (10-20 nmol/min per ml) generated by xanthine/xanthine oxidase. Oxygen radicals induced > 50% loss of PAF acetylhydrolase activity within 60 s and almost complete inactivation by 10 min. This phenomenon was irreversible and independent of oxidative modification of LDL. Inactivation occurred without changes in the affinity constant of the enzyme (Km was 17.9 microM under control conditions and 15.1 microM after exposure to oxygen radicals). Inactivation was prevented by the scavengers superoxide dismutase or dimethylthiourea or by the iron chelator deferoxamine. Thus, superoxide-mediated, iron-catalyzed formation of hydroxyl radicals can rapidly and irreversibly inactivate PAF acetylhydrolase. Since concomitant production of PAF and oxygen radicals can occur in various forms of tissue injury, inactivation of acetylhydrolase might represent one mechanism by which oxygen radicals may potentiate and prolong the proinflammatory effects of PAF.
Similar articles
-
Glycosylation enhances oxygen radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein.Basic Res Cardiol. 1997 Apr;92(2):96-105. doi: 10.1007/BF00805570. Basic Res Cardiol. 1997. PMID: 9166989
-
Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL.Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3505-12. doi: 10.1161/01.atv.17.12.3505. Arterioscler Thromb Vasc Biol. 1997. PMID: 9437199
-
Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.Biochem J. 2001 Jul 15;357(Pt 2):457-64. doi: 10.1042/0264-6021:3570457. Biochem J. 2001. PMID: 11439095 Free PMC article.
-
Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers.Prostaglandins Leukot Essent Fatty Acids. 1999 Aug;61(2):65-82. doi: 10.1054/plef.1999.0038. Prostaglandins Leukot Essent Fatty Acids. 1999. PMID: 10509861 Review.
-
PAF acetylhydrolase gene polymorphisms and asthma severity.Pharmacogenomics. 2001 Aug;2(3):163-75. doi: 10.1517/14622416.2.3.163. Pharmacogenomics. 2001. PMID: 11535107 Review.
Cited by
-
Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome.Auto Immun Highlights. 2018 Feb 10;9(1):2. doi: 10.1007/s13317-018-0103-3. Auto Immun Highlights. 2018. PMID: 29429123 Free PMC article. No abstract available.
-
Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.Mediators Inflamm. 2000;9(3-4):197-200. doi: 10.1080/09629350020002921. Mediators Inflamm. 2000. PMID: 11132779 Free PMC article.
-
Platelet-activating-factor-mediated pathogenesis in Lyme disease.Infect Immun. 1996 Mar;64(3):1026-9. doi: 10.1128/iai.64.3.1026-1029.1996. Infect Immun. 1996. PMID: 8641753 Free PMC article.
-
Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.J Clin Invest. 1997 Dec 1;100(11):2680-90. doi: 10.1172/JCI119813. J Clin Invest. 1997. PMID: 9389731 Free PMC article.
-
Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.Cardiovasc Drugs Ther. 1996 Sep;10(4):417-24. doi: 10.1007/BF00051106. Cardiovasc Drugs Ther. 1996. PMID: 8924055